In a meta-analysis of data from nearly 8000 patients reported in Clinical Infectious Diseases, researchers found significantly fewer drug resistance mutations, including NRTI-associated mutations, in people who had experienced treatment failure while taking first-line HIV treatment based on boosted PIs than in people taking NNRTI-based therapy.
Genotypic NNRTI resistance was much more common than PI resistance. The NRTI-associated M184V and (in non-AZT-containing regimens) K65R mutation were also more common in cases of NNRTI failure than of PI failure. These data were drawn from a meta-analysis of participants in 20 clinical trials for whom first-line treatment failure was seen after 48 weeks or less.
http://www.aidsmap.org/en/news/5D43C654-A08D-40C8-8777-84DA318F9DD8.asp